Compare MSA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSA | MIRM |
|---|---|---|
| Founded | 1914 | 2018 |
| Country | United States | United States |
| Employees | 5300 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.7B |
| IPO Year | N/A | 2019 |
| Metric | MSA | MIRM |
|---|---|---|
| Price | $171.93 | $94.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $197.40 | $115.33 |
| AVG Volume (30 Days) | 205.3K | ★ 702.8K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $6.78 | $26.22 |
| Revenue Next Year | $5.00 | $22.04 |
| P/E Ratio | $28.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $147.68 | $39.18 |
| 52 Week High | $208.92 | $109.28 |
| Indicator | MSA | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 48.08 |
| Support Level | $166.79 | $85.35 |
| Resistance Level | $175.73 | $98.03 |
| Average True Range (ATR) | 4.58 | 3.39 |
| MACD | 1.16 | 0.06 |
| Stochastic Oscillator | 67.89 | 20.06 |
MSA Safety Inc makes safety products that are used to protect workers in the oil and gas and mining industries. The company's product offerings include breathing apparatuses, fall protection, portable gas detection systems, industrial head protection, fire and rescue helmets, and fixed gas and flame detection systems, among others. The end markets for its products include the fire service, contractor, industrial, mining, oil and gas, and utilities industries. The company has organized its business into four geographical operating segments that are aggregated into two reportable segments: Americas and International. The majority of its revenue is generated from the Americas segment, which is comprised of the company's operations in Northern North America and Latin America geographies.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.